Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Magneto eTrieve thrombectomy system EIC funding application

Project description

New system for stroke and PE treatment

Current thrombectomy tools for treating stroke and pulmonary embolism (PE) rely on outward radial forces to disrupt and retrieve clots, which can limit treatment for distal occlusions and leave behind fragments. The need for modern technologies in European healthcare is critical, as strokes and PE are leading causes of death and disability, especially with an ageing population. The EIC-funded MGN-2024-10 project will develop a system that attracts clots with minimal vessel wall interaction, enabling access to distal locations and reducing fragmentation. It will be the first technology to utilise the electric properties of blood clots for removal. It targets a EUR 5 billion market for both PE and stroke in the EU and the United States.

Objective

In the fields of stroke and PE care, current thrombectomy tools rely on outward radial forces against the vessel wall to disrupt and retrieve clots limiting treatment of distal occlusions and potentially leaving clot fragments behind.
Generating an attachment force that is attractive by nature with the eTrieve™ system developed by Magneto allows to attract clot with minimal interaction with the vessel wall, enabling access to distal locations and minimizing fragmentation. The eTrieve™ system developed by Magneto is the first and only system that utilizes the electric properties of blood clots in order to facilitate their removal.
The urgent need to invest in modern technologies for European healthcare systems is underscored by the pressing issues of stroke and pulmonary embolism, major causes of death and disability worldwide. With aging being a primary risk factor for stroke and Europe's population aging rapidly, the incidence of these conditions is poised to skyrocket.
We founded Magneto in 2016, and target a total addressable market across both PE and stroke indications of €5B (EU+US markets), with a SAM totaling at €1B with device pricing aligned with reimbursement: $3-5k for stroke devices and $10k per procedure for PE.
Our team includes experienced MedTech industry veterans, with specific and extensive knowledge in the cardiovascular space, and a talented and creative R&D team constantly driving the company innovation forward.
At Magneto, our vision is not just about developing a device; it's about revolutionizing patient care for stroke and PE. Our ambitious goals encompass innovation, patient well-being, accessibility, clinical excellence, sustainability, and collaboration. Through our relentless pursuit of these ambitions, we are poised to leave an indelible mark on the field of thrombectomy technology, saving lives, improving outcomes, and inspiring positive change across the healthcare landscape.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

MAGNETO THROMBECTOMY SOLUTIONS LTD
Net EU contribution
€ 2 499 875,00
Address
6 NETANYAHU YEHONATAN STR.
6037604 OR YEHUDA
Israel
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data